Pharmaceutical giant GSK announced Wednesday it will acquire Canadian company 35Pharma for $950 million cash. The purchase gives GSK access to an experimental treatment for a deadly lung condition called pulmonary hypertension.

British pharmaceutical giant GSK announced Wednesday it will purchase Canadian biotechnology firm 35Pharma Inc for $950 million in cash, gaining access to a promising treatment for a serious lung condition.
This acquisition represents the second significant purchase made by GSK since Luke Miels took over as chief executive, following the company’s $2.2 billion agreement to acquire RAPT Therapeutics last month.
Through this transaction, GSK will obtain 35Pharma’s experimental medication designed to treat pulmonary hypertension, a deadly condition characterized by elevated blood pressure within the lungs that reduces patients’ life expectancy. This acquisition will strengthen GSK’s collection of respiratory treatments.
Earlier this week, the London-based pharmaceutical company also announced a separate $1 billion agreement to purchase worldwide development rights for two kidney disease therapies from Frontier Biotechnologies that use small interfering RNA technology.
Australian Tech Company Eliminates 2,000 Jobs Due to AI Automation
TikTok Parent Company ByteDance Soars to $550 Billion Valuation
Mexican Lawmakers Pass Bill to Shorten Work Week to 40 Hours by 2030